207 related articles for article (PubMed ID: 32141023)
1. Osilodrostat: First Approval.
Duggan S
Drugs; 2020 Apr; 80(5):495-500. PubMed ID: 32141023
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
[TBL] [Abstract][Full Text] [Related]
4. Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats.
Li L; Vashisht K; Boisclair J; Li W; Lin TH; Schmid HA; Kluwe W; Schoenfeld H; Hoffmann P
Toxicol Appl Pharmacol; 2015 Aug; 286(3):224-33. PubMed ID: 25981165
[TBL] [Abstract][Full Text] [Related]
5. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
[TBL] [Abstract][Full Text] [Related]
6. Osilodrostat oral tablets for adults with Cushing's disease.
Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas.
Tabarin A; Haissaguerre M; Lassole H; Jannin A; Paepegaey AC; Chabre O; Young J
Eur J Endocrinol; 2022 Jan; 186(2):K1-K4. PubMed ID: 34905500
[No Abstract] [Full Text] [Related]
8. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
[TBL] [Abstract][Full Text] [Related]
9. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
[TBL] [Abstract][Full Text] [Related]
10. Rapid control of severe ectopic Cushing's syndrome by oral osilodrostat monotherapy.
Bessiène L; Bonnet F; Tenenbaum F; Jozwiak M; Corchia A; Bertherat J; Groussin L
Eur J Endocrinol; 2021 May; 184(5):L13-L15. PubMed ID: 33667191
[No Abstract] [Full Text] [Related]
11. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.
Yin L; Lucas S; Maurer F; Kazmaier U; Hu Q; Hartmann RW
J Med Chem; 2012 Jul; 55(14):6629-33. PubMed ID: 22788843
[TBL] [Abstract][Full Text] [Related]
12. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
Dougherty JA; Desai DS; Herrera JB
Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
[TBL] [Abstract][Full Text] [Related]
13. Osilodrostat for the treatment of Cushing's disease.
Rasool S; Skinner BW
Expert Opin Pharmacother; 2021 Jun; 22(9):1099-1106. PubMed ID: 33703978
[TBL] [Abstract][Full Text] [Related]
14. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients.
Bonnet-Serrano F; Poirier J; Vaczlavik A; Laguillier-Morizot C; Blanchet B; Baron S; Guignat L; Bessiene L; Bricaire L; Groussin L; Assié G; Guibourdenche J; Bertherat J
Eur J Endocrinol; 2022 Aug; 187(2):315-322. PubMed ID: 35699971
[TBL] [Abstract][Full Text] [Related]
15. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
Paton DP
Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol.
Zhu W; Chen Z; Li Q; Tan G; Hu G
Curr Med Chem; 2016; 23(6):623-33. PubMed ID: 26795197
[TBL] [Abstract][Full Text] [Related]
17. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
18. Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism.
Ferriere A; Salenave S; Puerto M; Young J; Tabarin A
Eur J Endocrinol; 2024 Jan; 190(1):L1-L3. PubMed ID: 38123490
[TBL] [Abstract][Full Text] [Related]
19. Osilodrostat (Isturisa) for Cushing's disease.
Med Lett Drugs Ther; 2021 Feb; 63(1617):21-23. PubMed ID: 33647005
[No Abstract] [Full Text] [Related]
20. Pembrolizumab-induced cyclic ACTH-dependent Cushing's syndrome treated by a block-and-replace approach with osilodrostat.
Paepegaey AC; Dot JM; Beauvy J; Juttet P; Le Berre JP
Ann Endocrinol (Paris); 2022 Feb; 83(1):73-75. PubMed ID: 34871599
[No Abstract] [Full Text] [Related]
[Next] [New Search]